Analysts at Credit Suisse evaluated potential M&A in the biotech sector beyond Medivation (NASDAQ: MDVN), which in addition to a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE